Abstract PD07-05: In Situ Immune Response after Neoadjuvant Chemotherapy for Breast Cancer Predicts Survival

Purpose: Accumulating preclinical evidence suggest that anticancer immune responses contribute to the success of chemotherapy. However, the prognostic value of tumor infiltrating lymphocytes after neoadjuvant chemotherapy for breast cancer remains unknown. We hypothesized that the nature of the immune infiltrate following neoadjuvant chemotherapy would predict patient survival. Patients and Methods: In a series of 111 consecutive HER2 and a...